Sfoglia per AUTORE
APRILE G
Collezione AO Cuneo

  

Items : 14

Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice. in Cancers / Cancers (Basel). 2023 Jan 31;15(3):900. doi: 10.3390/cancers15030900.

2023
ASL Biella
AO Cuneo

Masi G; Aprile G; Fornaro L; De Manzoni G; Basile D; Bencivenga M; Vasile E; Leone F; Montagnani F; Puzzoni M; Scartozzi M; Ribero D; Vivaldi C; Fanotto V; Salani F;

TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. in Cancers / Cancers (Basel). 2021 Jun 7;13(11):2839. doi: 10.3390/cancers13112839.

2021
AO Ordine Mauriziano
AO Cuneo

Zaniboni A; Tamburini E; Tamberi S; Strippoli A; Spallanzani A; Smiroldo V; Silvestris N; Ratti M; Pucci F; Ongaro E; Murialdo R; Lonardi S; Iachetta F; Granetto C; Fornaro L; Frassineti GL; Di Maio M; De Vita F; De Manzoni G; Cardellino GG; Berardi R; Aprile G; Antonuzzo L; Aglietta M; Prisciandaro M; Di Bartolomeo M; Palermo F; Raimondi A; Cremolini C; et alii...

Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Aug;153:16-26. doi: 10.1016/j.ejca.2021.04.039. Epub 2021 Jun 12.

2021
AO Cuneo

Falcone A; Masi G; Fontanini G; Ugolini C; Bertolini AS; Germani MM; Clavarezza M; Frassoldati A; Granetto C; Conca V; Lonardi S; Aprile G; Tomasello G; Pietrantonio F; Boccaccino A; Passardi A; Poma AM; Moretto R; Giordano M; Cremolini C;

Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2020 Nov;139:81-89. doi: 10.1016/j.ejca.2020.08.009. Epub 2020 Sep 23.

2020
AO Cuneo

Aprile G; Falcone A; Grande R; Boccaccino A; Fea E; Tamburini E; Bordonaro R; Marmorino F; Buonadonna A; Pietrantonio F; Zaniboni A; Antoniotti C; Caponnetto S; Tomasello G; Cupini S; Santini D; Bergamo F; Lonardi S; Zucchelli G; Moretto R; Rossini D; Cremolini C;

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. in The Lancet. Oncology / Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.

2020
AOU Città della Salute di Torino
AO Cuneo

Fenocchio E; Mammoliti S; Cupini S; Roselli M; Mambrini A; Ritorto G; Clavarezza M; Carlomagno C; Di Donato S; Ronzoni M; Masi G; Tomasello G; Antonuzzo L; Corallo S; Cordio S; Moretto R; Buonadonna A; Granetto C; Murgioni S; Zaniboni A; Aprile G; Grande R; Marmorino F; Passardi A; Santini D; Tamburini E; Latiano TP; Bordonaro R; Pietrantonio F; et alii...

Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer. in Cancer chemotherapy and pharmacology / Cancer Chemother Pharmacol. 2019 Nov;84(5):1089-1096. doi: 10.1007/s00280-019-03943-x. Epub 2019 Sep

2019
AO Cuneo

Venturini F; Bianco S; Tralongo P; Stroppolo ME; Latiano TP; Granetto C; Germano D; Giuliani F; Di Stasi A; Di Donato S; Dell'Aquila E; Di Bisceglie M; Delfanti S; Cordio S; Buccafusca G; Carlomagno C; Brugnatelli S; Bilancia D; Leo S; Avallone A; Aprile G; Rosati G; Addeo R;

Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2019 Mar;109:175-182. doi: 10.1016/j.ejca.2018.12.028. Epub 2019 Feb 5.

2019
AO Cuneo

Fontanini G; Lonardi S; Sensi E; Tonini G; Schirripa M; Granetto C; Delfanti S; Di Donato S; Casagrande M; Gemma D; Borelli B; Allegrini G; Murgioni S; Antoniotti C; Dell'Aquila E; Masi G; Salvatore L; Aprile G; Bergamo F; Marmorino F; Cremolini C; Boni L; Falcone A;

Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2019 Dec 1;30(12):1969-1977. doi: 10.1093/annonc/mdz403.

2019
AO Cuneo

Marmorino F; Rossini D; Lonardi S; Moretto R; Zucchelli G; Aprile G; Dell'Aquila E; Ratti M; Bergamo F; Masi G; Urbano F; Ronzoni M; Libertini M; Borelli B; Randon G; Buonadonna A; Allegrini G; Pella N; Ricci V; Boccaccino A; Latiano TP; Cordio S; Passardi A; Tamburini E; Boni L; Falcone A; Cremolini C;

Correlation between values of specific biomarkers and outcome in metastatic colorectal cancer patients treated with regorafenib in Annals of Oncology

2019
AO Cuneo
AOU Città della Salute di Torino

Ricci V; Falletta A; Granetto C; Paccagnella M; Abbona A; Fea E; Fabozzi T; Lo Nigro C; Merlano M; Zucchelli G; Marmorino F; Rossini D; Aprile G; Casagrande M; Lonardi S; Murgioni S; Dell'Aquila E; Tomasello G; Moretto R; Antoniotti C; Borelli B; Urbano F; Ronzoni M; Zaniboni A; Manglaviti S; Buonadonna A; Ritorto G; Masi G; Allegrini G; et alii...

Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC in Journal of Clinical Oncology

2019
AO Cuneo

Cremolini C; Antoniotti C; Lonardi S; Rossini D; Pietrantonio F; Cordio SS; Bergamo F; Marmorino F; Maiello E; Passardi A; Masi G; Tamburini E; Santini D; Grande R; Zaniboni A; Granetto C; Murgioni S; Aprile G; Boni L; Falcone A;

Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2017 Mar;73:74-84. doi: 10.1016/j.ejca.2016.10.028. Epub 2016 Dec 13.

2017
AO Cuneo

Pellegrinelli A; Sensi E; Pilati P; Cillo U; Urbani L; Granetto C; Ferrari L; Allegrini G; Tonini G; Tomasello G; Zucchelli G; Marmorino F; Pietrantonio F; Moretto R R; Masi G; Bergamo F; Aprile G; Loupakis F; Cremolini C; Casagrande M; Milione M; Fontanini G; Falcone A;

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. in BMC cancer / BMC Cancer. 2017 Jun 9;17(1):408. doi: 10.1186/s12885-017-3360-z.

2017
AO Cuneo

Santini D; Allegrini G; Di Donato S; Passardi A; Tomasello G; Valsuani C; Pietrantonio F; Ronzoni M; Ricci V; Tamburini E; Aprile G; Lonardi S; Zagonel V; Boni L; Schirripa M; Salvatore L; Antoniotti C; Masi G; Loupakis F; Marmorino F; Cremolini C; Falcone A;

Treatments (tx) after progression to first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and MOMA studies by GONO group in Journal of Clinical Oncology

2017
AO Cuneo

Rossini D; Moretto R; Cremolini C; Zagonel V; Tonini G; Ricci V; Aprile G; Lonardi S; Tomasello G; Dell'Aquila E; Allegrini G; Bergamo F; Mancini M; Antoniotti C; Ronzoni M; Zaniboni A; Marmorino F; Bustreo S; Mori E; Falcone A;

Ethics in oncology: principles and responsibilities declared in the Italian Ragusa statement. in Tumori / Tumori. 2016 Dec 1;102(6):e25-e27. doi: 10.5301/tj.5000582.

2016
AO Ordine Mauriziano
AO Cuneo

Bordonaro R; Labianca R; Micallo G; Fioretto L; Zagonel V; Merlano M; Passalacqua R; Crispino S; Di Costanzo F; De Cicco M; Mancuso A; Omodeo Salè E; Di Maio M; Perrone F; Nicolis F; Iacono C; Spinsanti S; Comandone A; Marchetti P; Aprile G; Caminiti C; Pinto C; Gori S;